Want to see DE:MED full AI Analyst Report?
MED Stock Chart & Stats
€4.26
-€0.10(-2.35%)
At close: 4:00 PM EDT
€4.26
-€0.10(-2.35%)
Day’s Range― - ―
52-Week Range€2.88 - €4.40
Previous CloseN/A
Volume15.80K
Average Volume (3M)5.25K
Market Cap
€195.70M
Enterprise Value€493.77
Total Cash (Recent Filing)€77.39M
Total Debt (Recent Filing)€382.37M
Price to Earnings (P/E)6.9
Beta0.24
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.97%
Share Statistics
EPS (TTM)0.61
Shares Outstanding47,500,000
10 Day Avg. Volume4,347
30 Day Avg. Volume5,253
Financial Highlights & Ratios
PEG Ratio1.78
Price to Book (P/B)0.71
Price to Sales (P/S)0.22
P/FCF Ratio3.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.78
Revenue Forecast (FY)€805.60M
Bulls Say, Bears Say
Bulls Say
Improving Revenue & ProfitabilitySustained revenue growth (~6.6% TTM) alongside a return to positive net and EBIT margins indicates the core hospital, rehab and nursing businesses are stabilizing. This supports durable cash generation, continued reinvestment in facilities and gradual margin expansion versus prior loss years.
Consistent Free Cash FlowConsistently positive FCF and strong operating cash flow provide lasting financial flexibility to fund capex, service debt and invest in care capacity. Reliable cash generation reduces refinancing risk and supports long-term operational resilience in a capital-intensive care facilities business.
Improving Leverage Trend & ROEA meaningful decline in debt-to-equity from earlier highs and a recovered ROE (~11.9%) signal improving balance-sheet health. This structural deleveraging trajectory enhances credit flexibility over months, enabling strategic investments or targeted debt reduction without sacrificing service delivery.
Bears Say
Still-Elevated LeverageDespite improvement, a ~1.5x debt-to-equity ratio leaves the firm more sensitive to revenue or reimbursement shocks than less-levered peers. Persistent leverage limits strategic flexibility, increases interest and refinancing exposure, and constrains capacity for large capital projects or acquisitions.
Modest Margins & Data CautionModest sector-relative margins reduce buffers against cost inflation and staffing pressures. The noted inconsistency in gross-profit data also undermines confidence in margin forecasting accuracy, complicating budgeting and longer-term margin-improvement plans for management and investors.
Moderate Cash ConversionOperating cash flow and FCF absorb a meaningful share of earnings due to working-capital and capex demands. This moderates the company's ability to accelerate debt paydown or fund growth initiatives from internally generated cash, leaving reliance on external financing if needs rise.
MED FAQ
What was MEDICLIN AG’s price range in the past 12 months?
MEDICLIN AG lowest stock price was €2.88 and its highest was €4.40 in the past 12 months.
What is MEDICLIN AG’s market cap?
MEDICLIN AG’s market cap is €195.70M.
When is MEDICLIN AG’s upcoming earnings report date?
MEDICLIN AG’s upcoming earnings report date is Nov 05, 2026 which is in 90 days.
How were MEDICLIN AG’s earnings last quarter?
MEDICLIN AG released its earnings results on Jul 30, 2026. The company reported €0.206 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is MEDICLIN AG overvalued?
According to Wall Street analysts MEDICLIN AG’s price is currently Overvalued.
Does MEDICLIN AG pay dividends?
MEDICLIN AG pays a Annually dividend of €0.04 which represents an annual dividend yield of 0.97%. See more information on MEDICLIN AG dividends here
What is MEDICLIN AG’s EPS estimate?
MEDICLIN AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MEDICLIN AG have?
MEDICLIN AG has 47,500,000 shares outstanding.
What happened to MEDICLIN AG’s price movement after its last earnings report?
MEDICLIN AG reported an EPS of €0.206 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.966%.
Which hedge fund is a major shareholder of MEDICLIN AG?
Currently, no hedge funds are holding shares in DE:MED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MEDICLIN Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.90%
12-Months-Change
Fundamentals
Return on Equity
0.97%
Trailing 12-Months
Asset Growth
-6.44%
Trailing 12-Months
Company Description
MEDICLIN AG
Mediclin AG is a German healthcare enterprise primarily engaged in managing hospitals across the nation. Its operations are categorized into three main segments: Post-Acute, Acute, and various other related activities. The company offers a comprehensive range of medical specializations, encompassing fields such as neurology, psychosomatics, orthopaedics, internal medicine, cardiology, oncology, geriatrics, psychiatry, and surgical interventions, in addition to general nursing care. Furthermore, Mediclin provides specialized services like ear, nose, and throat (ENT) treatment and acute outpatient care. As of December 31, 2021, its extensive network comprised 34 clinics, 7 nursing care facilities, and 11 medical care centres. This infrastructure collectively provided a significant capacity of 7,831 beds and 482 nursing places, distributed across eleven of Germany's federal states. The company's corporate headquarters are situated in Offenburg, Germany.
Technical Analysis
RHON-KLINIKUM AG
―
MATERNUS-Kliniken AG
―
Limes Schlosskliniken AG
―
Gesundheitswelt Chiemgau AG
―
M1 Kliniken AG
―